Six Stages of Engagement in ADHD Treatment Described by Diverse, Urban Parents

Abstract. Objective: We examined predictors and moderators of treatment outcome in mothers and children diagnosed with ADHD in a large multicentre RCT. Method: In total, 144 mother-child dyads with ADHD were randomly assigned to either a maternal ADHD treatment (group psychotherapy and open methylphenidate medication, TG) or to a control treatment (individual counselling without psycho- or pharmacotherapy, CG). After maternal ADHD treatment, parent-child training (PCT) for all mother-child dyads was added. The final analysis set was based on 123 dyads with completed primary outcome assessments (TG: n = 67, CG: n = 56). The primary outcome was the change in each child’s externalizing symptoms. Multiple linear regression analyses were performed. Results: The severity of the child’s externalizing problem behaviour in the family at baseline predicted more externalizing symptoms in the child after PCT, independent of maternal treatment. When mothers had a comorbid depression, TG children showed more externalizing symptoms after PCT than CG children of depressive mothers. No differences between the treatment arms were seen in the mothers without comorbid depression. Conclusions: Severely impaired mothers with ADHD and depressive disorder are likely to need additional disorder-specific treatment for their comorbid psychiatric disorders to effectively transfer the contents of the PCT to the home situation (CCTISRCTN73911400).

Download Full-text

Parental Preferences and Goals Regarding ADHD Treatment

PEDIATRICS ◽

10.1542/peds.2013-0152d ◽

2013 ◽

Vol 132 (4) ◽

pp. X12-X12

Keyword(s):

Parental Preferences ◽

Adhd Treatment

Download Full-text

Detecting Potential Adverse Drug Reactions of Preschool ADHD Treatment Using Health Consumer-Generated Content

2020 IEEE International Conference on Healthcare Informatics (ICHI) ◽

10.1109/ichi48887.2020.9374395 ◽

2020 ◽

Author(s):

Heejun Kim ◽

Ou Stella Liang ◽

Christopher C. Yang

Keyword(s):

Adverse Drug Reactions ◽

Drug Reactions ◽

Health Consumer ◽

Adhd Treatment

Download Full-text

Role of the norepinephrine transporter polymorphisms in atomoxetine treatment: From response to side effects in children with ADHD

Journal of Psychopharmacology ◽

10.1177/02698811211015245 ◽

2021 ◽

pp. 026988112110152

Author(s):

Melike Kevser Gul ◽

Elif Funda Sener ◽

Muge Gulcihan Onal ◽

Esra Demirci

Keyword(s):

Side Effects ◽

Treatment Response ◽

Large Population ◽

Norepinephrine Transporter ◽

Response To Treatment ◽

Nucleotide Polymorphisms ◽

Children With Adhd ◽

Real Time Quantitative Pcr ◽

Treatment Side Effects ◽

Adhd Treatment

Objective: Atomoxetine (ATX), one of the most commonly used drugs after stimulants in attention deficit hyperactivity disorder (ADHD) treatment, is an inhibitor of the norepinephrine transporter ( NET/SLC6A2), which is also associated with the etiology of ADHD. In this study, we aimed to investigate the effect of NET gene polymorphisms on response to ATX treatment and to find the answers to the questions about whether there is a relationship between the severity of the disorder and the observed side effects in children with ADHD. Method: About 100 children with ADHD and 80 healthy controls (HCs) were included in this study. The dose of ATX was started at 0.5 mg/kg/day and titrated at 1.2 mg/kg/day. Response to treatment of 78 patients was evaluated 2 months after the beginning of the treatment. After whole blood samples were obtained, DNAs were isolated, and samples were stored at −80°C. Two single-nucleotide polymorphisms (SNPs) (rs12708954 and rs3785143) were analyzed by real-time quantitative PCR (qRT-PCR). Results: The patients with both rs12708954 and rs3785143 heterozygous genotype had better treatment response and more side effects than patients with wild type. There was not found any association between any of the investigated NET polymorphisms and ADHD severity. Conclusion: It was, however, found that the NET rs12708954 and rs3785143 genotypes affect the treatment response to ATX in our study; thus, further studies with a large population are needed to understand the effects of NET polymorphisms on treatment, side effects, and also the severity of ADHD.

Download Full-text

Stakeholder-Generated Implementation Strategies to Promote Evidence-Based ADHD Treatment in Community Mental Health

Administration and Policy in Mental Health and Mental Health Services Research ◽

10.1007/s10488-021-01143-5 ◽

2021 ◽

Author(s):

Margaret H. Sibley ◽

Mercedes Ortiz ◽

Alexandria Rios-Davis ◽

Courtney A. Zulauf-McCurdy ◽

Paulo A. Graziano ◽

...

Keyword(s):

Mental Health ◽

Community Mental Health ◽

Implementation Strategies ◽

Evidence Based ◽

Adhd Treatment

Download Full-text

ADHD TREATMENT IN LATIN AMERICA AND THE CARIBBEAN

Journal of the American Academy of Child & Adolescent Psychiatry ◽

10.1097/chi.0b013e31816c0008 ◽

2008 ◽

Vol 47 (6) ◽

pp. 721-722 ◽

Cited By ~ 11

Author(s):

Guilherme Polanczyk ◽

Luis Augusto Rohde ◽

Claudia Szobot ◽

Marcelo Schmitz ◽

Cecilia Montiel-Nava ◽

...

Keyword(s):

Latin America ◽

Adhd Treatment ◽

The Caribbean

Download Full-text

Neurobiology and Genetics of ADHD in Adults

CNS Spectrums ◽

10.1017/s1092852900026833 ◽

2008 ◽

Vol 13 (S13) ◽

pp. 5-7 ◽

Cited By ~ 3

Author(s):

Thomas J. Spencer

Keyword(s):

Adult Adhd ◽

Extended Release ◽

Treatment Strategies ◽

Stimulant Use ◽

Hyperactivity Disorder ◽

Adhd Treatment ◽

Norepinephrine Reuptake Inhibitor ◽

Adults And Children ◽

Core Symptoms ◽

Adhd Medications

AbstractTreatment of attention-deficit/hyperactivity disorder (ADHD) may positively impact the neurobiology of adult patients with ADHD. Treatment may also minimize impairment from core symptoms and may alter the course of co-morbid disorders such as depression and substance use disorder. However, much of the information on stimulant use in adult ADHD comes from studies conducted in children, and it remains unclear whether there is a difference between children and adults when it comes to the side effects and tolerability of ADHD treatments. It is known that clinical presentation differs between adults and children, with adults demonstrating a higher percentage of mood disorders. Current treatments for adult ADHD include psychosocial therapies and pharmacologic therapies, the latter of which include the stimulants d-methylphenidate extended release (XR), OROS methylphenidate, lisdexamfetamine, and mixed amphetamine salts XR; and the nonstimulant atomoxetine, a selective norepinephrine reuptake inhibitor. There is need for additional study of treatment strategies for adult ADHD. Although all classes of ADHD medications are approved in adults, there are fewer approved formulations for adults than for children. Efficacy in adults is more subjective than in children, which may affect how efficacy rates for adult treatments are calculated. Adults also present a greater diversion risk than children. In addition, there are several new and emerging medication treatments worth considering.This Expert Roundtable Supplement represents part 2 of a 3-part supplement series on adult ADHD led by Lenard A. Adler, MD. In this activity, Thomas J. Spencer, MD, discusses the neurobiology and genetics of adult ADHD; Mark A. Stein, PhD, discusses stimulant therapy; and Jeffrey H. Newcorn, MD, reviews nonstimulants and psychosocial treatments.

Download Full-text